![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aplastic anaemia (AA) consists of pancytopenia and empty bone marrow. Its incidence varies worldwide but predominates in developing countries. Diverse aetiologies are involved, with autoimmunity at the centre of the p-icture. For the 70% of patients with the severe and very severe forms of AA and who lack a human leukocyte antigen (HLA)-matched sibling, immunosuppressive therapy (IST) is key in treating the disease, with a remission rate close to 70%, an 80 – 90% 5-year survival rate in responding patients and a relapse rate close to 10%. For the 30% with a sibling donor available, h-aematopoietic stem cell transplant (HSCT) from bone marrow or peripheral blood has up to a 90% chance of cure, with a 5 – 10% graft rejection/failure rate. Patients who fail IST (25 – 30%) and lack a sibling donor can benefit from CD34+-enriched, p-artially T cell-depleted unrelated stem cell transplants, with a g-eneral survival rate up to 37%, the newest source of stem cells for this modality being cord blood. Non-myeloablative, irradiation-free co-nditioning regimens offer appreciable benefits, and new immunosuppressive agents, such as fludarabine and alemtuzumab, have been incorporated with promising preliminary results. Graft-versus-host disease, graft failure and infections remain significant challenges in HSCT for which innovative treatment strategies are being developed at present.